1. Japanese clinical practice guidelines for prostate cancer 2023.
- Author
-
Kohjimoto, Yasuo, Uemura, Hiroji, Yoshida, Masahiro, Hinotsu, Shiro, Takahashi, Satoru, Takeuchi, Tsutomu, Suzuki, Kazuhiro, Shinmoto, Hiroshi, Tamada, Tsutomu, Inoue, Takahiro, Sugimoto, Mikio, Takenaka, Atsushi, Habuchi, Tomonori, Ishikawa, Hitoshi, Mizowaki, Takashi, Saito, Shiro, Miyake, Hideaki, Matsubara, Nobuaki, Nonomura, Norio, and Sakai, Hideki
- Subjects
- *
PROSTATE cancer , *MEDICAL quality control , *PROSTATE cancer patients - Abstract
This fourth edition of the Japanese Clinical Practice Guidelines for Prostate Cancer 2023 is compiled. It was revised under the leadership of the Japanese Urological Association, with members selected from multiple academic societies and related organizations (Japan Radiological Society, Japanese Society for Radiation Oncology, the Department of EBM and guidelines, Japan Council for Quality Health Care (Minds), Japanese Society of Pathology, and the patient group (NPO Prostate Cancer Patients Association)), in accordance with the Minds Manual for Guideline Development (2020 ver. 3.0). The most important feature of this revision is the adoption of systematic reviews (SRs) in determining recommendations for 14 clinical questions (CQs). Qualitative SRs for these questions were conducted, and the final recommendations were made based on the results through the votes of 24 members of the guideline development group. Five algorithms based on these results were also created. Contents not covered by the SRs, which are considered textbook material, have been described in the general statement. In the general statement, a literature search for 14 areas was conducted; then, based on the general statement and CQs of the Japanese Clinical Practice Guidelines for Prostate Cancer 2016, the findings revealed after the 2016 guidelines were mainly described. This article provides an overview of these guidelines. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF